AFT Forsyth & Company Inc. Purchases New Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• AFT Forsyth & Company Inc. initiated a new position in Thermo Fisher Scientific in the fourth quarter, buying 3,753 shares worth about $2.175 million. The stock now represents roughly 0.9% of the firm’s holdings.
• Thermo Fisher’s latest earnings beat estimates, with quarterly EPS of $5.44 versus $5.25 expected and revenue of $11.01 billion versus $10.86 billion expected. Revenue rose 6.2% year over year, and the company kept FY2026 EPS guidance at $24.640 to $25.120.
• Analyst sentiment remains constructive, with multiple firms issuing buy or outperform ratings and a consensus “Moderate Buy” rating. The average price target stands at $608.95, above the recent share price of $468.80.

AFT Forsyth & Company Inc. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 3,753 shares of the medical research company's stock, valued at approximately $2,175,000. Thermo Fisher Scientific makes up approximately 0.9% of AFT Forsyth & Company Inc.'s holdings, making the stock its 22nd biggest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atlas Capital Advisors Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $195,000. Altrafin AG purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $934,000. Cordoba Advisory Partners LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $236,000. Kestra Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 2.4% in the 4th quarter. Kestra Advisory Services LLC now owns 27,816 shares of the medical research company's stock worth $16,118,000 after purchasing an additional 660 shares in the last quarter. Finally, Transamerica Financial Advisors LLC lifted its stake in Thermo Fisher Scientific by 41.7% in the 4th quarter. Transamerica Financial Advisors LLC now owns 8,879 shares of the medical research company's stock worth $5,145,000 after purchasing an additional 2,615 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company's stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $468.80 on Friday. The company has a fifty day simple moving average of $479.14 and a two-hundred day simple moving average of $527.68. The company has a market cap of $174.22 billion, a price-to-earnings ratio of 25.77, a price-to-earnings-growth ratio of 2.08 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific's payout ratio is 10.34%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TMO. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price target for the company. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a "strong-buy" rating in a report on Friday, April 24th. Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Morgan Stanley reaffirmed an "overweight" rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Finally, Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research report on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $608.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.